TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6407714

Group type: EXPERIMENTAL
Intervention: 25 mg/kg vitamin E (DL‐alpha‐tocopherol acetate) intramuscularly after birth (day 0) and on days 1, 2, and 3
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 44
Study: 30747897

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy combined with chemotherapy (docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy combined with abiraterone
Number of subjects: 0
Study: 30477839

Group type: EXPERIMENTAL
Intervention: 30 mg/day saffron for 8 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo capsules for 8 weeks
Number of subjects: 54
Study: 26065721

Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sarcopenic patients with normal BMI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sarcopenic obese patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-sarcopenic patients
Number of subjects: 72
Study: 24619599

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) treatment
Number of subjects: 482

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 482
Study: 22801094

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (3.75 µg HA/AS03A or 1.9 µg HA/AS03B)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted 15 µg HA vaccine
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted 7.5 µg HA vaccine
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: All vaccines except nonadjuvanted 7.5 µg HA vaccine
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines
Number of subjects: 322
Study: 19847482

Group type: EXPERIMENTAL
Intervention: Doxorubicin-Lipiodol emulsion (group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: DC Beads loaded with doxorubicin (group II)
Number of subjects: 20
Study: 16904254

Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Number of subjects: 52
Study: 15738746

Group type: EXPERIMENTAL
Intervention: Pregabalin 200 mg/d (BID)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin 400 mg/d (BID)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d (TID)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin (all dosages)
Number of subjects: 341
Study: 11954670

Group type: EXPERIMENTAL
Intervention: Therapeutic biking using a wheelchair bicycle in a recreation therapy protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic biking
Number of subjects: 0
Study: 10454438

Group type: EXPERIMENTAL
Intervention: 3-week high potassium diet (80 mmol/24 h)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual diet control group
Number of subjects: 58
Study: 8851001

Group type: EXPERIMENTAL
Intervention: Smokers occupationally exposed to organic solvents
Number of subjects: 139

Group type: COMPARATOR
Intervention: Nonsmokers occupationally exposed to organic solvents
Number of subjects: 139

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 139
Study: 2181674

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 233

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 233
Study: 393383

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/week of 5-fluorouracil by oral route
Number of subjects: 57

Group type: COMPARATOR
Intervention: 15 mg/kg/week of 5-fluorouracil by iv route
Number of subjects: 57
Study: 30606886

Group type: EXPERIMENTAL
Intervention: Exemestane for 5 years
Number of subjects: 3159

Group type: COMPARATOR
Intervention: Sequential treatment of tamoxifen followed by exemestane for 5 years
Number of subjects: 3159
Study: 28893875

Group type: EXPERIMENTAL
Intervention: 1 mg zoledronate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2.5 mg zoledronate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 160

Group type: COMPARATOR
Intervention: zoledronate (1-5 mg)
Number of subjects: 160
Study: 26172564

Group type: EXPERIMENTAL
Intervention: GDM patients
Number of subjects: 0
Study: 23129746

Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Busulfan plus fludarabine (BuFlu)
Number of subjects: 126
Study: 20831649

Group type: EXPERIMENTAL
Intervention: Priorix™ (Glaxo Smithkline Biologicals)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MMRII® (Merck & Co., Inc.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Priorix™ and MMRII®
Number of subjects: 160
Study: 19496762

Group type: EXPERIMENTAL
Intervention: +4 degrees C Ringer's solution with a target temperature of 33 degrees C
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 37
Study: 16943110

Group type: EXPERIMENTAL
Intervention: Insulin (0.3 IU/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 15457411

Group type: EXPERIMENTAL
Intervention: Smooth stem (Ra 17)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Rough stem (Ra 170)
Number of subjects: 237
Study: 12369275

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 9820990

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Site-selective protocol (recombinant tissue plasminogen activator in anterior acute myocardial infarction, streptokinase in non-anterior acute myocardial infarction)
Number of subjects: 0
Study: 7641666

Group type: EXPERIMENTAL
Intervention: Experimental videotape with a culturally relevant context emphasizing personal loss
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gender-ethnicity-matched control condition (videotape presented by an African American woman)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ethnicity-matched information control videotape
Number of subjects: 100
Study: 2766658

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 60
Study: 16339

Group type: EXPERIMENTAL
Intervention: rimiterol
Number of subjects: 60

Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 60
Study: 31982915

Group type: EXPERIMENTAL
Intervention: Headgear Activator (HGA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Twin-Block (TB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both HGA and TB
Number of subjects: 52
Study: 27846092

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic‐euglycemic clamp (0.1 U/kg/hr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 30
Study: 25786741

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Major Depression
Number of subjects: 250
Study: 23295625

Group type: EXPERIMENTAL
Intervention: NaF/SiO2‐based toothpaste (1,100 µg F/g as labeled, 1,129.7 ± 49.4 µg F/g soluble fluoride as analyzed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Na2FPO3/CaCO3‐based toothpaste (1,450 µg F/g as labeled, 1,122.4 ± 76.4 µg F/g soluble fluoride as analyzed)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 20
Study: 20702058

Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation programme
Number of subjects: 143

Group type: COMPARATOR
Intervention: Individual counselling programme
Number of subjects: 143
Study: 19812173

Group type: EXPERIMENTAL
Intervention: Prenatal food supplementation fortified with multiple micronutrients (FFS)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: MMN supplementation (control)
Number of subjects: 1296
Study: 16900825

Group type: EXPERIMENTAL
Intervention: Noble-metal metal-ceramic crowns
Number of subjects: 95
Study: 15020281

Group type: EXPERIMENTAL
Intervention: Dexamethasone before chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 95
Study: 11736726

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (proton pump inhibitor-based)
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Successfully H. pylori eradicated patients
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Unsuccessfully H. pylori eradicated patients
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Healing rates
Number of subjects: 2102
Study: 10212830

Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to STZ diabetic rats and rhesus monkeys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to humans with impaired glucose tolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to women with PCOS
Number of subjects: 0
Study: 30151230

Group type: EXPERIMENTAL
Intervention: Soy protein (S)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-soy protein (NS)
Number of subjects: 71
Study: 28271532

Group type: EXPERIMENTAL
Intervention: Strip patch test
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional patch test
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nickel sulfate 5% pet.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Potassium dichromate 0.5% pet.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lanolin alcohol 30% pet.
Number of subjects: 132
Study: 25667975

Group type: EXPERIMENTAL
Intervention: Combined cytology and bi-marker CADM1/MAL-methylation analysis
Number of subjects: 364

Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 364
Study: 22992166

Group type: EXPERIMENTAL
Intervention: Lokomat(®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Over-ground gait training (OGT)
Number of subjects: 20
Study: 19476623

Group type: EXPERIMENTAL
Intervention: Non-cemented hemiarthroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 200
Study: 17348460

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) followed by cisplatin (75 mg/m2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2 i.v.) and cyclophosphamide (700 mg/m2 i.v.)
Number of subjects: 120
Study: 15096238

Group type: EXPERIMENTAL
Intervention: Delta9 Tetrahydrocannabinol (THC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of THC and CBD
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11230751

Group type: EXPERIMENTAL
Intervention: Combination of interferon (IFN) and ribavirin for either 24 or 48 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of interferon (IFN) and ribavirin
Number of subjects: 124
Study: 9648961

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. (BD group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. (ICS group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol (BD group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol (ICS group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 32
Study: 8076625

Group type: EXPERIMENTAL
Intervention: Semisolid carbohydrate intake (S)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Equal energy fluid intake (F)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluid placebo (P)
Number of subjects: 32
Study: 2916540

Group type: EXPERIMENTAL
Intervention: Know Your Body program
Number of subjects: 1234
Study: 799978

Group type: EXPERIMENTAL
Intervention: Maprotiline 25 mg orally twice daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Diazepam 5 mg orally twice daily
Number of subjects: 126
Study: 31676109

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31500557

Group type: EXPERIMENTAL
Intervention: Oscillatory transcranial direct current stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 27753785

Group type: EXPERIMENTAL
Intervention: Physical activity meeting recommendations
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Higher mean daily intensity level of 10-minute activity sessions
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Good cardiorespiratory fitness (highest tertile)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Highest third for the modified push-up test
Number of subjects: 219
Study: 25413377

Group type: EXPERIMENTAL
Intervention: Linezolid continuous infusion (CI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Linezolid intermittent infusion (II)
Number of subjects: 22
Study: 24151141

Group type: EXPERIMENTAL
Intervention: Exposure-based psychotherapy for PTSD (8 sessions)
Number of subjects: 92
Study: 21688301

Group type: EXPERIMENTAL
Intervention: Etanercept (50mg subcutaneously weekly)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Etanercept and Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IMACS and other outcome measures
Number of subjects: 16
Study: 19879233

Group type: COMPARATOR
Intervention: Tat vaccine administered 5 times monthly, subcutaneously in alum or intradermically alone at 7.5 microg, 15 microg or 30 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tat vaccine
Number of subjects: 0
Study: 17726413

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 10-15 mcg/kg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intravenous morphine sulfate (IV morphine) 0.1 mg/kg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both OTFC and IV morphine
Number of subjects: 87
Study: 15478494

Group type: EXPERIMENTAL
Intervention: 1.8% hydrogen peroxide strips
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3.3% hydrogen peroxide strips
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide strips
Number of subjects: 37
Study: 11419655

Group type: EXPERIMENTAL
Intervention: KPI‐185
Number of subjects: 0

Group type: COMPARATOR
Intervention: KPI‐wild type
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 0
Study: 9577286

Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of local anaesthetics)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 19
Study: 7697403

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium supplementation and fish oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretics and dietary salt reduction
Number of subjects: 0
Study: 3126349

Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min
Number of subjects: 129

Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 129
Study: 31805922

Group type: EXPERIMENTAL
Intervention: Seal&Protect® (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DentinoCer (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No surface treatment (Group A)
Number of subjects: 60
Study: 28285395

Group type: EXPERIMENTAL
Intervention: OR-fill
Number of subjects: 59

Group type: COMPARATOR
Intervention: PACU-fill
Number of subjects: 59
Study: 25463415

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided arm
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Treatment-related SAEs
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Patients experiencing SAEs
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Patients in the highest risk quartile
Number of subjects: 151
Study: 23458225

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 40 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 7.5 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 132
Study: 21206244

Group type: EXPERIMENTAL
Intervention: Schizophrenia spectrum disorders
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Physical anhedonia
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Social and physical anhedonia
Number of subjects: 263
Study: 19476983

Group type: EXPERIMENTAL
Intervention: Transcutaneous interferential (IF) electrostimulation; 18 courses, 20 minutes, 3 times per week, low-frequency current, duration of 250 microseconds, repetition time of 6.6 seconds.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 17904983

Group type: EXPERIMENTAL
Intervention: Terbutaline (250 microg intravenously)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nitroglycerin (400 microg intravenously)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 110
Study: 15150840

Group type: EXPERIMENTAL
Intervention: Test formulation of combined AZT/3TC tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study: 11488797

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (patients undergoing surgery for non-malignant conditions)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Postoperative period (3 months following tumour resection)
Number of subjects: 44
Study: 9631330

Group type: EXPERIMENTAL
Intervention: Single Axis (SA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Seattle Lite (SL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flex Foot (FF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transtibial amputees (TT) overall
Number of subjects: 9
Study: 7998630

Group type: EXPERIMENTAL
Intervention: HIV/AIDS intervention group
Number of subjects: 197

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 197
Study: 2662700

Group type: EXPERIMENTAL
Intervention: Methionyl GH (somatrem), 2 IU per m2 body surface s.c. daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30148987

Group type: EXPERIMENTAL
Intervention: Conbercept (0.5 mg) administered intravitreally once monthly for the first 3 months, then once quarterly until month 12.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham control group received first 3 monthly sham injections followed by 3 monthly injections of conbercept (0.5 mg) until month 12.
Number of subjects: 114
Study: 27149055

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 120

Group type: COMPARATOR
Intervention: 400 IU vitamin D3
Number of subjects: 120
Study: 25010554

Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22170716

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (2 mg/d) for the first 6 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) for the remaining 18 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: GH therapy
Number of subjects: 16
Study: 20128040

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Muscle relaxant medication
Number of subjects: 28
Study: 17912222

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) with conventional dialysis solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icodextrin based solution
Number of subjects: 0
Study: 16288443

Group type: EXPERIMENTAL
Intervention: Extracorporeal blood oxygenation and ozonation (EBOO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous prostacyclin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EBOO
Number of subjects: 28

Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 28
Study: 12163294

Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation (HFPV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 35
Study: 10450629

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study: 8677156

Group type: EXPERIMENTAL
Intervention: Cytostatic agents (VCR + Rub, L‐aspa, CY, Ara‐C)
Number of subjects: 21
Study: 2337243

Group type: EXPERIMENTAL
Intervention: Extradural adrenaline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Warm injectate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Extradural fentanyl
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 120341

Group type: EXPERIMENTAL
Intervention: Doleron (dextropropoxyphene, acetylsalicylic acid, phenazone, caffeine and Transergan)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Astra 2167 (dextropropoxyphene and acetylsalicylic acid)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 31986446

Group type: EXPERIMENTAL
Intervention: Participation in a medicine take-back program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Willingness to pay for a medicine disposal program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to participate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to pay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current disposal practices
Number of subjects: 0
Study: 31490546

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 884

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 884